How to treat a patient with thromboangiitis obliterans: a systematic review

B Fazeli, MD Moghadam, S Niroumand - Annals of vascular surgery, 2018 - Elsevier
To date, there is still no treatment protocol for patients with thromboangiitis obliterans (TAO)
who are also afflicted with critical limb ischemia (CLI). Smoking cessation on its own cannot …

Recent advances of oxidative stress in thromboangiitis obliterans: biomolecular mechanisms, biomarkers, sources and clinical applications

Q Chen, J Chen, J Li, Y Cheng, R Zhang, Z Liu - Thrombosis Research, 2023 - Elsevier
Oxidative stress (OS) has been identified as a key factor in the development of
Thromboangiitis Obliterans (TAO). The detection of OS levels in clinical and scientific …

Corticotrophins, Corticosteroids and Prostaglandins

J Costa, M Farré - Side Effects of Drugs Annual, 2014 - Elsevier
Abstract The Side Effects of Drugs Annuals forms a series of volumes in which the adverse
effects of drugs and adverse reactions to them are surveyed. The series supplements the …

Perfusions intraveineuses d'Iloprost: profil des patients et tolérance

F Catros - 2013 - policycommons.net
Introduction: les perfusions d'Iloprost sont utilisées dans le traitement des troubles
trophiques liés aux artériopathies de causes diverses et des phénomènes de Raynaud …

First report of compartment syndrome: case report

GP Thomas - Reactions, 2011 - Springer
A 48-year-old man developed a compartment syndrome during treatment with iloprost for
critical limb ischaemia secondary to Buerger's disease. The man was admitted with …

First reports of serious adverse drug reactions in recent weeks

ME Welzen, GE van den Berk, RL Hamers - Ann Fr Anesth Reanim, 2011 - Springer
First reports of serious adverse drug reactions in recent weeks Page 1 DRUG REACTIONS
AND INTERACTIONS First reports of serious adverse drug reactions in recent weeks The …